Introduction
LabGenius Therapeutics is a London-based biotechnology company founded in 2012 that discovers therapeutic antibodies by combining machine learning with high-throughput robotic experimentation. James Field, a protein engineer by training, founded LabGenius during his PhD at Imperial College London and serves as chief executive officer per the company team page reviewed in July 2026. Brel verified the official website as labgeniustx.com — the CSV domain labgenics.com is incorrect and labgenius.com no longer resolves.
LabGenius operates a hybrid model: partnering with pharmaceutical companies while advancing wholly owned pipeline assets, distinguishing it from pure AI software vendors that stop at target nomination without IND-track molecules.
What the company does
LabGenius built EVA — a discovery platform that generates antibody design hypotheses, tests them in automated cell-based assays, and uses resulting data to refine machine learning models iteratively. The approach targets multispecific antibodies where on-target, off-tumour toxicity limits existing immunotherapies, especially in solid tumours expressing tumour-associated antigens like Nectin-4 at low levels on healthy tissue.
Lead internal program LGTX-101 is a trivalent VHH-based Nectin-4 x CD3 T-cell engager designed with avidity-driven selectivity — LabGenius cites greater than 70,000-fold killing selectivity in functional assays and complete tumour regression in vivo on its pipeline page. June 18, 2026 LG Chem collaboration extends EVA to next-generation multispecific antibodies for solid tumours per the official press release.
Who it serves
LabGenius serves pharmaceutical partners including Sanofi — with an expanded 2025 antibody optimisation collaboration and ESMO IO poster presentation — and LG Chem following the June 2026 multi-year research agreement. Investors including top-tier VCs cited on the team page have funded more than $75 million across Series B and subsequent rounds supporting platform maturation and pipeline progression toward clinic.
Pharma discovery teams evaluate LabGenius on throughput of optimized multispecific designs, selectivity data from functional screens, and partnership structures that share risk on solid tumour T-cell engager programs where ADC toxicity histories create skepticism.
Company background
Field founded LabGenius in 2012 with conviction that robotic experimentation platforms would autonomously discover therapeutic antibodies faster than manual lab iteration alone. The company raised a £35 million Series B Field described in a personal blog post on labgeniustx.com, bringing strategic investors alongside existing backers. Field’s team page biography notes R&D partnerships with leading pharma and maturation of EVA from research prototype to partnership-grade discovery engine.
Product and AI capabilities
EVA integrates ML-driven protein engineering with synthetic biology and robotic automation — closing the design-build-test-learn loop inside LabGenius facilities rather than outsourcing validation to CRO timelines measured in quarters. Multispecific antibody optimization requires functional cell killing data ML models cannot infer from sequence alone; EVA’s high-throughput experimentation supplies the labels that make selectivity optimization tractable.
LGTX-101 exemplifies the output: a highly selective TCE addressing Nectin-4 solid tumours where ADC approaches face dose-limiting toxicities from antigen expression on normal tissues — a design problem Field’s June 2026 LG Chem release frames as central to safer immunotherapies.
Key developments
2012: LabGenius founded in London by James Field. £35M Series B announced per company blog. December 2025: ESMO IO poster and expanded Sanofi collaboration. June 18, 2026: LG Chem research collaboration press release (labgeniustx.com, official source). Website verified at labgeniustx.com replacing incorrect CSV labgenics.com.
Why it matters
LabGenius matters because AI drug discovery narratives often stop at in silico hits without selective multispecific antibodies advancing toward clinic. EVA-produced LGTX-101 selectivity data gives Brel readers a concrete benchmark for ML-driven antibody engineering versus traditional display libraries. LabGenius sits alongside BenchSci in UK-Canada biotech AI coverage but owns wet-lab automation and pipeline assets BenchSci does not.
Sector context
LabGenius belongs in Brel’s AI in healthcare coverage under biotechnology and AI drug discovery, related to TechBio companies like Recursion Pharmaceuticals but focused on therapeutic antibody optimization rather than phenotypic small-molecule screening.
Sources and references
LabGenius LG Chem press release (June 18, 2026) and team page. Website corrected to labgeniustx.com.
- LabGenius — LG Chem collaboration (labgeniustx.com, June 18, 2026)
- LabGenius — Team (labgeniustx.com)
Reviewed July 10, 2026. James Field is CEO. CSV website labgenics.com replaced with labgeniustx.com.